Trials / Completed
CompletedNCT04264312
Baseline Investigation of Chronic Hepatitis B Viruses Infections: Who is Eligible for Treated Criteria
Beijing Center for Disease Prevention and Control
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 76,220 (actual)
- Sponsor
- Wu Jiang · Other Government
- Sex
- All
- Age
- 25 Years
- Healthy volunteers
- Not accepted
Summary
Through two-stage stratified cluster sampling, investigators studied the antiviral treatment rate and the main factors affecting the antiviral treatment in community chronic HBV infection-related liver disease population.
Detailed description
Hepatitis B virus (HBV) infection is a major public health problem worldwide. China has the world's largest burden of HBV infection and will be a major contributor towards the global elimination of hepatitis B disease by 2030. While, the antiviral treatment rate and the main factors affecting the antiviral treatment in community chronic HBV infections is still unknown. In response to the above situation, Sampling applied a two-stage stratified cluster sampling design in 16 Districts and 331 Townships. Investigators wanted to know the one who is eligible for treated criteria based on community in 25 and over years old in Beijing.
Conditions
Timeline
- Start date
- 2017-07-28
- Primary completion
- 2019-09-28
- Completion
- 2020-01-10
- First posted
- 2020-02-11
- Last updated
- 2020-02-11
Locations
11 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04264312. Inclusion in this directory is not an endorsement.